Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Free Cash Flow (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Free Cash Flow readings, the most recent being -$468000.0 for Q4 2025.

  • Quarterly Free Cash Flow rose 75.65% to -$468000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.2 million through Dec 2025, down 8.59% year-over-year, with the annual reading at -$9.2 million for FY2025, 8.59% down from the prior year.
  • Free Cash Flow hit -$468000.0 in Q4 2025 for Oramed Pharmaceuticals, up from -$1.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.1 million in Q2 2024 and bottomed at -$11.6 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$4.2 million, with a median of -$3.4 million recorded in 2021.
  • Peak annual rise in Free Cash Flow hit 178.22% in 2024, while the deepest fall reached 878.79% in 2024.
  • Oramed Pharmaceuticals' Free Cash Flow stood at -$6.9 million in 2021, then decreased by 21.25% to -$8.4 million in 2022, then soared by 83.02% to -$1.4 million in 2023, then crashed by 35.26% to -$1.9 million in 2024, then skyrocketed by 75.65% to -$468000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Free Cash Flow are -$468000.0 (Q4 2025), -$1.6 million (Q3 2025), and -$3.5 million (Q2 2025).